Reprogramming macrophages via immune cell mobilized hydrogel microspheres for osteoarthritis treatments
Source abstract
Abstract
Regulating macrophage activation precisely is crucial in treating chronic inflammation in osteoarthritis (OA). However, the stable pro-inflammatory state and deep distribution of macrophages in vivo pose a great challenge to treatment. In this study, inspired by the innate immune, immune cell mobilized hydrogel microspheres were constructed by microfluidic methods and load chemokines, macrophage antibodies and engineered cell membrane vesicles (sEVs) via covalent and non-covalent junctions. The immune cell mobilized hydrogel microspheres, based on a mixture of streptavidin grafted hyaluronic acid methacrylate (HAMA-SA) and Chondroitin sulfate methacrylate (ChSMA) microspheres (HCM), can recruit, capture and reprogram proinflammatory macrophages in the joint cavity to improve the joint inflammatory microenvironment. In vitro experiments demonstrated that immune cell mobilized hydrogel microspheres had excellent macrophage recruitment, capture, and reprogramming abilities. Pro-inflammatory macrophages can be transformed into anti-inflammatory macrophages with an efficiency of 88.5 %. Animal experiments also revealed significant reduction in synovial inflammation and cartilage matrix degradation of OA. Therefore, the immune cell mobilized hydrogel microspheres may be an effective treatment of OA inflammation for the future.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Osteoarthritis Treatment and Mechanisms · Extracellular vesicles in disease · Mesenchymal stem cell research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Osteoarthritis10.1016/S0140-6736(19)30417-9 ↗
2. Progress in osteoarthritis research by the national natural science foundation of China10.1038/s41413-022-00207-y ↗
3. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis10.1038/nrrheum.2016.136 ↗
4. Synovial inflammation in osteoarthritis progression10.1038/s41584-022-00749-9 ↗
5. Osteoarthritis: pathogenic signaling pathways and therapeutic targets10.1038/s41392-023-01330-w ↗
6. Synovial macrophages: from ordinary eaters to extraordinary multitaskers10.1016/j.it.2021.03.002 ↗
7. Tissue-specific macrophages: how they develop and choreograph tissue biology
8. Macrophages in health and disease10.1016/j.cell.2022.10.007 ↗
9. Joint synovial macrophages as a potential target for intra-articular treatment of osteoarthritis-related pain10.1016/j.joca.2021.11.014 ↗
10. Mitochondrial dysfunction prevents repolarization of inflammatory macrophages10.1016/j.celrep.2016.09.008 ↗
11. Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors10.1016/j.celrep.2021.109955 ↗
12. Synovial macrophage and fibroblast heterogeneity in joint homeostasis and inflammation10.3389/fmed.2022.862161 ↗
13. Locally renewing resident synovial macrophages provide a protective barrier for the joint10.1038/s41586-019-1471-1 ↗
14. Location, location, location: how the tissue microenvironment affects inflammation in RA10.1038/s41584-020-00570-2 ↗
15. Immune resolution mechanisms in inflammatory arthritis10.1038/nrrheum.2016.193 ↗
16. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity10.1038/s41586-020-2015-4 ↗
17. Overview of the immune response10.1016/j.jaci.2009.12.980 ↗
18. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme10.1007/s11060-010-0389-0 ↗
19. Smart magnetic drug delivery systems for the treatment of cancer10.3390/nano13050876 ↗
20. Tumor hijacks macrophages and microbiota through extracellular vesicles
21. Cell migration: implications for repair and regeneration in joint disease10.1038/s41584-018-0151-0 ↗
22. Macrophage 3D migration: a potential therapeutic target for inflammation and deleterious progression in diseases10.1016/j.phrs.2021.105563 ↗
23. Human interleukin-4-treated regulatory macrophages promote epithelial wound healing and reduce colitis in a mouse model10.1126/sciadv.aba4376 ↗
24. Injectable microfluidic hydrogel microspheres for cell and drug delivery10.1002/adfm.202170227 ↗
25. Charge‐guided micro/nano‐hydrogel microsphere for penetrating cartilage matrix10.1002/adfm.202107678 ↗
26. Injectable hydrogel microspheres with self-renewable hydration layers alleviate osteoarthritis10.1126/sciadv.abl6449 ↗
27. Stem cell‐recruiting injectable microgels for repairing osteoarthritis10.1002/adfm.202170357 ↗
28. Material stiffness influences the polarization state, function and migration mode of macrophages10.1016/j.actbio.2019.02.048 ↗
29. Extracellular vesicles as a next-generation drug delivery platform10.1038/s41565-021-00931-2 ↗
30. Extracellular vesicles: biology and emerging therapeutic opportunities10.1038/nrd3978 ↗
31. Mitochondria-rich extracellular vesicles from autologous stem cell-derived cardiomyocytes restore energetics of ischemic myocardium10.1016/j.jacc.2020.12.060 ↗
32. Artificial exosomes for translational nanomedicine10.1186/s12951-021-00986-2 ↗
33. Cell membrane-derived vesicle: a novel vehicle for cancer immunotherapy
34. Reprogramming mitochondrial metabolism in synovial macrophages of early osteoarthritis by a camouflaged meta‐defensome
35. Silencing Smad7 potentiates BMP2-induced chondrogenic differentiation and inhibits endochondral ossification in human synovial-derived mesenchymal stromal cells10.1186/s13287-021-02202-2 ↗
36. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry10.1038/s41590-019-0378-1 ↗
37. Engineered mesenchymal stem cell-derived extracellular vesicles: a state-of-the-art multifunctional weapon against Alzheimer's disease10.7150/thno.81860 ↗
38. Assessment of joint pharmacokinetics and consequences for the intraarticular delivery of biologics10.1016/j.jconrel.2022.06.015 ↗
39. Intra-articular drug delivery for osteoarthritis treatment10.3390/pharmaceutics13122166 ↗
40. Chondroitin sulfate microspheres anchored with drug-loaded liposomes play a dual antioxidant role in the treatment of osteoarthritis10.1016/j.actbio.2022.07.052 ↗
41. Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection10.1002/bit.24605 ↗
42. The membrane receptor CD44: novel insights into metabolism10.1016/j.tem.2022.02.002 ↗
43. Native joint-resident mesenchymal stem cells for cartilage repair in osteoarthritis10.1038/nrrheum.2017.182 ↗
44. Evolution and function of interleukin-4 receptor signaling in adaptive immunity and neutrophils10.1038/s41435-020-0095-7 ↗
45. Matrix metalloproteinases in arthritis: towards precision medicine10.1038/s41584-023-00966-w ↗
46. ADAMTS5 as a therapeutic target for osteoarthritis: mendelian randomisation study10.1136/annrheumdis-2021-222007 ↗
47. Advanced microfluidic devices for fabricating multi‐structural hydrogel microsphere
48. Reprogramming stem cells in regenerative medicine
49. Stimuli‐responsive hydrogels: fabrication and biomedical applications10.1002/VIW.20200112 ↗
50. Granular hydrogels for 3D bioprinting applications10.1002/VIW.20200060 ↗